Skip to main content
. 2023 Dec 22;8(24):e173688. doi: 10.1172/jci.insight.173688

Figure 4. MIG6 depletion confers resistance to ALK inhibitors in vivo.

Figure 4

(A and B) JFCR-028-3 control and MIG6-knockout cells were subcutaneously injected into BALB/c nude mice. The mice were treated with vehicle, alectinib (10 mg/kg) orally, or alectinib plus panitumumab (0.5 mg, twice a week) intraperitoneally for 4 weeks (n = 6). Data are presented as the mean ± SEM; *P < 0.05 (1-way ANOVA following Dunnett’s test). Images of xenograft tumors on day 37 after the initial treatment are shown in B. The black bar indicates 1 cm. (C) JFCR-028-3 sg-control or sgMIG6 tumor–bearing mice were treated with alectinib, with or without panitumumab for 2 days, and 3 hours after the treatment on day 2, mice were euthanized; the tumors were taken for immunoblot analysis with the indicated antibodies.